

## Letter to the Editor

# Ivermectin and COVID-19

Viroj Wiwanitkit

Department of Community Medicine, DY Patil University, Pune, Maharashtra, India

**Submitted:** 31 Aug 2020

**Accepted:** 12 Jan 2021

**Online:** 21 Apr 2021

To cite this article: Wiwanitkit V. Ivermectin and COVID-19. *Malays J Med Sci.* 2021;**28(2)**:177. <https://doi.org/10.21315/mjms2021.28.2.17>

To link to this article: <https://doi.org/10.21315/mjms2021.28.2.17>

Dear Editor,

I would like to share ideas on the publication 'Ivermectin: potential role as repurposed drug for COVID-19' (1). Dixit et al. (1) discussed 'the potential for ivermectin to be used as a therapeutic option in COVID-19. In fact, many classic drugs are proposed as potential therapeutic agents against COVID-19. Hydroxychloroquine is a good example (2). Ivermectin, is another potential drug for COVID-19 therapy. In some countries such as India, ivermectin is used for mass chemoprophylaxis of lymphatic filariasis. Nevertheless, there is a high incidence of COVID-19 in the area that ivermectin is routinely used. Therefore, a standard prophylactic dose of ivermectin might not be useful for COVID-19 therapy. Since ivermectin is a classic drug with safety evidence, further trials on ivermectin against COVID-19 are recommended. In some countries such as India, ivermectin is used for mass chemoprophylaxis of lymphatic filariasis (3).

### Acknowledgements

None.

### Conflict of interest

None.

### Funds.

None.

### Correspondence

Professor Viroj Wiwanitkit  
PhD, MD (Chulalongkorn University, Bangkok Thailand)  
DY Patil University,  
Lohgaon, Airport Rd, Charholi Budruk,  
Pune, Maharashtra 412105, India.  
Tel: +91 20 6711 6400  
E-mail: [wviroj@yahoo.com](mailto:wviroj@yahoo.com)

### References

1. Dixit A, Yadav R, Singh AV. Ivermectin: potential role as repurposed drug for COVID-19. *Malays J Med Sci.* 2020;**27(4)**:154–158. <https://doi.org/10.21315/mjms2020.27.4.15>
2. Joob B, Wiwanitkit V. Evidence of protective effect of hydroxychloroquine on COVID-19. *J Rheumatol.* 2020;**47(10)**:1587. <https://doi.org/10.3899/jrheum.200638>
3. Al-Kubati AS, Al-Samie AR, Al-Kubati S, Ramzy RMR. The story of lymphatic filariasis elimination as a public health problem from Yemen. *Acta Trop.* 2020;**212**:105676. <https://doi.org/10.1016/j.actatropica.2020.105676>